Z 2-(butyl)but-2-enoic acid | 105027-57-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Z 2-(butyl)but-2-enoic acid
• 英文别名: (2Z)-2-ethylidenehexanoic acid
• CAS: 105027-57-4
• 化学式: C₈H₁₄O₂
• 分子量: 142.198
• InChiKey: BSUKKOMNQGNSGP-DAXSKMNVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• NEW COMPOUNDS
  申请人：Hauel Norbert

  公开号：US20110098282A1

  公开（公告）日：2011-04-28

  Novel compounds of which the following is exemplary:

  新颖的化合物，以下是其中的一个例子：
• [EN] NOVEL CYP17 INHIBITORS/ANTIANDROGENS<br/>[FR] NOUVEAUX INHIBITEURS DE CYP17/ANTIANDROGÈNES
  申请人：ORION CORP

  公开号：WO2014202827A1

  公开（公告）日：2014-12-24

  Compounds of formula (I), wherein R1 to R8 A, B, Z1 and Z2 are as defined in the claims and pharmaceutically acceptable salts and esters thereof are disclosed. The compounds of formula (I) possess utility as androgen receptor antagonists (inhibitors) and/or cytochrome P450 monooxygenase 17a-hydroxylase/17,20-lyase (CYP17) inhibitors. The compounds are useful as medicaments in the treatment of cancer, particularly prostate cancer, and other androgen dependent conditions and diseases where androgen antagonism is desired.

  公式（I）的化合物，其中R1至R8，A，B，Z1和Z2如权利要求中所定义，并且其药用盐和酯被披露。公式（I）的化合物具有作为雄激素受体拮抗剂（抑制剂）和/或细胞色素P450单加氧酶17a-羟化酶/17,20-裂解酶（CYP17）抑制剂的效用。这些化合物在治疗癌症，特别是前列腺癌，以及其他需要雄激素拮抗作用的疾病和情况中作为药物是有用的。
• PROCESS FOR PRODUCING 2-ETHYLHEPTANOIC ACID
  申请人：Boeing Christian

  公开号：US20140194648A1

  公开（公告）日：2014-07-10

  Process for producing 2-ethylheptanoic acid.

  制备2-乙基庚酸的过程。
• Beneficial agent delivery systems
  申请人：Bruza J. Kenneth

  公开号：US20060018977A1

  公开（公告）日：2006-01-26

  An improved fragrance delivery system capable of providing controlled release of fragrance molecules in various consumer products is composed of a polymer having covalently bound fragrance moieties that are releasable in the form of fragrance molecules. Certain embodiments comprise globular polymer particles in which unbound fragrance molecules are occluded, absorbed and/or adsorbed. Certain other embodiments incorporate fragrance monomer units, which achieve reduced residuals upon complete release of the fragrance.

  一种改进的香气释放系统，能够在各种消费品中提供香气分子的受控释放，由具有共价结合的香气基团的聚合物组成，这些基团可以以香气分子的形式释放。某些实施例包括球形聚合物颗粒，其中未结合的香气分子被包含、吸收和/或吸附。某些其他实施例包括香气单体单元，这些单元在完全释放香气后实现减少残留物。
• [EN] HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS SPIRO HÉTÉROCYCLIQUES ET MÉTHODES D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2022083569A1

  公开（公告）日：2022-04-28

  Provided are compounds of Formula (I) having activity as inhibitors of G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and uses and methods of treating certain disorders, such as cancer, including but not limited to lung, pancreatic and colorectal cancers.

  提供的是具有抑制G12C突变KRAS蛋白活性的化合物(I)的公式，包括这些化合物的制药组合物，以及治疗某些疾病（如癌症，包括但不限于肺癌、胰腺癌和结肠直肠癌）的用途和方法。